ES2106042T3 - Inhibidores de la incorporacion de calcio. - Google Patents

Inhibidores de la incorporacion de calcio.

Info

Publication number
ES2106042T3
ES2106042T3 ES91115932T ES91115932T ES2106042T3 ES 2106042 T3 ES2106042 T3 ES 2106042T3 ES 91115932 T ES91115932 T ES 91115932T ES 91115932 T ES91115932 T ES 91115932T ES 2106042 T3 ES2106042 T3 ES 2106042T3
Authority
ES
Spain
Prior art keywords
inhibitors
calcium incorporation
incorporation inhibitors
calcium
thrombocies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91115932T
Other languages
English (en)
Inventor
Robert J Dinerstein
David M Stemerick
Michael L Edwards
Keith A Diekema
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2106042T3 publication Critical patent/ES2106042T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/08—Preparation by ring-closure
    • C07D213/09—Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles
    • C07D213/10—Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles from acetaldehyde or cyclic polymers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)

Abstract

ESTA INVENCION SE REFIERE AL 1-ARIL-3-PIRIDINIL-2-PROPENO-1-UNOS Y A LAS COMPOSICIONES FAMACOLOGICAS QUE CONTIENE ESTOS COMPUESTOS COMO INGREDIENTES ACTIVOS Y QUE SON UTILES COMO INHIBIDORES DE LA ABSORCION DE CALCIO EN LEUCOCITOS Y TROMBOCITOS, Y EL PROCESO DE SU PREPARACION.
ES91115932T 1990-09-20 1991-09-19 Inhibidores de la incorporacion de calcio. Expired - Lifetime ES2106042T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58541290A 1990-09-20 1990-09-20

Publications (1)

Publication Number Publication Date
ES2106042T3 true ES2106042T3 (es) 1997-11-01

Family

ID=24341317

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91115932T Expired - Lifetime ES2106042T3 (es) 1990-09-20 1991-09-19 Inhibidores de la incorporacion de calcio.

Country Status (19)

Country Link
US (1) US5500429A (es)
EP (1) EP0476646B1 (es)
JP (1) JP3031766B2 (es)
KR (1) KR100198040B1 (es)
CN (1) CN1063685A (es)
AT (1) ATE154011T1 (es)
AU (1) AU653957B2 (es)
CA (1) CA2051494C (es)
DE (1) DE69126392T2 (es)
ES (1) ES2106042T3 (es)
FI (1) FI914409L (es)
HU (1) HUT59099A (es)
IE (1) IE913300A1 (es)
IL (1) IL99515A0 (es)
NO (1) NO913684L (es)
NZ (1) NZ239864A (es)
PT (1) PT99011A (es)
TW (1) TW205548B (es)
ZA (1) ZA917371B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2051504C (en) * 1990-09-20 2003-04-15 Robert J. Dinerstein 1-phenyl-3-aryl-2-propyne-1-ones as calcium uptake inhibitors
KR0130883Y1 (ko) * 1994-02-02 1998-12-15 김광호 컴퓨터의 하드 디스크 드라이버 착탈장치
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
EP1632281B1 (en) 2003-12-15 2011-09-14 Rohm And Haas Company Process for absorbing hydrophobic substances in polymers having an hollow structure
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
KR20080002850A (ko) 2005-03-23 2008-01-04 액테리온 파마슈티칼 리미티드 신규한 티오펜 유도체
US7723378B2 (en) 2005-03-23 2010-05-25 Actelion Pharmaceuticals Ltd. Hydrogenated benzo (C) thiophene derivatives as immunomodulators
EP1896446A1 (en) 2005-06-24 2008-03-12 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives
KR100779610B1 (ko) * 2005-09-13 2007-11-28 영남대학교 산학협력단 1-퓨란-2-일-3-피리딘-2-일-프로페논을 함유하는혈관신생으로 인한 질환 및 암질환의 예방 또는 치료용약학조성물
WO2007032591A1 (en) * 2005-09-13 2007-03-22 Industry-Academic Cooperation Foundation, Yeungnam University Composition comprising 1-furan-2-yl-3-pyridin-2-yl-pr0pen0ne having anti-angiogenic activity and cancer growth inhibitory activity
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
ATE447568T1 (de) 2006-01-24 2009-11-15 Actelion Pharmaceuticals Ltd Neue pyrinderivate
TWI408139B (zh) 2006-09-07 2013-09-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
TWI392671B (zh) 2006-09-07 2013-04-11 Actelion Pharmaceuticals Ltd 吡啶-４-基衍生物
ES2400163T3 (es) 2006-09-08 2013-04-08 Actelion Pharmaceuticals Ltd. Derivados de piridil-3-ilo como agentes de inmunomodulación
PT2125797E (pt) 2007-03-16 2014-03-11 Actelion Pharmaceuticals Ltd Derivados aminopiridina como agonistas do receptor s1p1/edg1
HRP20130641T1 (en) 2008-03-07 2013-08-31 Actelion Pharmaceuticals Ltd. Pyridin-2-yl derivatives as immunomodulating agents
CN102471328B (zh) 2009-07-16 2015-04-01 埃科特莱茵药品有限公司 吡啶-4-基衍生物
WO2011109551A2 (en) * 2010-03-03 2011-09-09 Calcimedica Inc. Compounds that modulate intracellular calcium
HRP20150919T1 (hr) 2011-01-19 2015-09-25 Actelion Pharmaceuticals Ltd. Derivati 2-metoksi-piridin-4-ila
JP2014100171A (ja) * 2012-11-16 2014-06-05 Hayashi Bussan Co Ltd 商品落下防止具
BR112017024785B1 (pt) 2015-05-20 2022-05-17 Idorsia Pharmaceuticals Ltd Forma cristalina do composto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4] oxadiazol-3- il]-2-etil-6-metilfenoxi}-propano-1,2-diol, composição farmacêutica, e, uso

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409424A (en) * 1966-03-01 1968-11-05 Ethyl Corp Propynones as defoliants
FR2081591A1 (en) * 1970-03-27 1971-12-10 Unicler 2, 4-dimethoxyphenyl beta-pyrid-4-ylvinyl ketone - for treating capillary fragility and permeability
BE789099A (fr) * 1971-09-22 1973-03-21 Boehringer Sohn Ingelheim Nouveaux derives de la pyridine et procede pour les fabriquer
FR2387956A1 (fr) * 1977-04-20 1978-11-17 Unicler Derives de la pyridine et leur preparation
US4582836A (en) * 1985-01-09 1986-04-15 Mcneilab, Inc. Octahydroindolizine compounds useful as analgesics
DK49688A (da) * 1987-03-20 1988-09-21 Hoffmann La Roche Propiolophenonderivater

Also Published As

Publication number Publication date
US5500429A (en) 1996-03-19
KR100198040B1 (ko) 1999-06-15
HU913010D0 (en) 1992-01-28
NO913684D0 (no) 1991-09-19
DE69126392D1 (de) 1997-07-10
NZ239864A (en) 1994-05-26
KR920006316A (ko) 1992-04-27
CA2051494A1 (en) 1992-03-21
FI914409A0 (fi) 1991-09-19
FI914409A7 (fi) 1992-03-21
AU653957B2 (en) 1994-10-20
EP0476646B1 (en) 1997-06-04
JP3031766B2 (ja) 2000-04-10
AU8452991A (en) 1992-03-26
JPH06271540A (ja) 1994-09-27
CA2051494C (en) 2006-03-14
EP0476646A1 (en) 1992-03-25
NO913684L (no) 1992-03-23
DE69126392T2 (de) 1998-01-22
ATE154011T1 (de) 1997-06-15
HUT59099A (en) 1992-04-28
TW205548B (es) 1993-05-11
PT99011A (pt) 1992-08-31
IL99515A0 (en) 1992-08-18
IE913300A1 (en) 1992-02-25
FI914409L (fi) 1992-03-21
CN1063685A (zh) 1992-08-19
ZA917371B (en) 1992-06-24

Similar Documents

Publication Publication Date Title
ES2106042T3 (es) Inhibidores de la incorporacion de calcio.
PA8462401A1 (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
ES2067154T3 (es) Dibenzoilalquilcianohidracinas.
ES2045110T3 (es) Mejoras en o relacionadas con antagonistas de leucotrienos.
HN1999000080A (es) Derivados de isotiazol utiles como agentes anticancerosos.
ES2183937T3 (es) Inhibidores de la adhesion celular.
MX9709874A (es) N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
PA8462201A1 (es) Compuestos de benceno sustituidos, procedimientos para su preparacion, y composiciones herbicidas y defoliantes que los contienen
ES2087850T3 (es) Proteinas antimicrobianas, composiciones que las contienen y sus aplicaciones.
MX9300603A (es) Derivados tiaciclicos de piperidinilo.
GT199800083A (es) Agonistas de prostaglandinas.
GT199800106A (es) Azetidinas.
ES2052463T1 (es) Antihipercolesterolemicos.
ES2082074T3 (es) 1,3-difenil-2-propin-1-onas.
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
CO5221025A1 (es) 4-trifluorometil-3-oxazolilpiridinas, procedimiento para su preparacion, agentes que las contienen y su uso como agente para la lucha contra organismos daninos
ES2080063T3 (es) Composiciones sinergicas que contienen imazalil.
ES2163186T3 (es) Composicion que comprende mupirocina y clorhexidina.
DE69905700D1 (de) Desinfizierende Zusammensetzung
ES2079539T3 (es) Inhibidores de la captacion de calcio.
ES2079034T3 (es) Composicion para inhibir la floracion de las plantas y composicion para prolongar la duracion de la floracion de las plantas.
GT199400055A (es) Metodo para la preparacion de 3-(heterociclilo biciclicos)-6-fluoroalquiluracilos
ES2189206T3 (es) Beta-alcoxiacrilatos contra la malaria.
ES2056562T3 (es) Ciclohexanodionas sustituidas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 476646

Country of ref document: ES